FierceBiotech Names Alector as One of Its "Fierce 15" Biotech

FierceBiotech Names Alector as One of Its "Fierce 15" Biotech

SAN FRANCISCO – Sept. 30, 2015 – Alector LLC, a biotech company pioneering the discovery of first-in-class, immuno-modulatory therapies for dementia and neuro-degeneration, announced today that it has been named by FierceBiotech as one of 2015's "Fierce 15" biotechnology companies. The award recognizes Alector as one of today's most promising private biotechnology companies.

To date, Alector has raised $48 million to advance its broad portfolio of therapeutics, which mobilize the immune system to treat Alzheimer's disease and other neurodegenerative disorders.

"We are developing drug leads against unique, genetically-validated neuro-immune targets through a novel, hypothesis-driven approach to neurodegeneration. We thank FierceBiotech for recognizing the potential of our strategy," said Arnon Rosenthal, Ph.D., co-founder, president and CEO of Alector.

The "Fierce 15" celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's 13th annual "Fierce 15" selection. A complete list of "Fierce 15" companies can be found online, here.

Every year FierceBiotech, an internationally recognized daily report, evaluates hundreds of private companies from around the world for its annual "Fierce 15" list.  FierceBiotech's editors base their selections for this yearly list on a variety of factors, such as the strength of each company's technology, partnerships, venture backers and a competitive market position.

Alector is currently hiring exceptional immunologists and neurobiologists at all levels. Outstanding candidates can find more information at www.alector.com.

About Alector

Alector LLC is a hypothesis-driven, neurology-focused, drug discovery and development start up. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics for Alzheimer's disease and other forms of dementia and neurodegeneration. Our strategy is to efficiently generate function modulating antibody drugs that engage, genetically validated, disease-altering, targets. Alector's approach is enabled by a strategic alliance with Adimab, the technology leader in the discovery of fully human antibodies and bispecifics. For more information, contact [email protected] www.alector.com

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than
 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.

Contacts:

Chris Erdman

MacDougall Biomedical Communications

781-235-3060

[email protected]

Rebecca Friend

FierceBiotech

202-824-5050

[email protected]arkets.com

Suggested Articles

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.

Durect's treatment lowered scores that reflect the likelihood a person with alcoholic hepatitis will die within a certain time in all 19 patients.

AstraZeneca is confident data generated across development show the antibody works despite a pivotal study missing its primary endpoint.